Quviviq Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Quviviq Availability in 2026

Dual orexin receptor antagonists (DORAs) have emerged as a valuable addition to the insomnia treatment toolkit, and Quviviq (Daridorexant) — the most recently approved DORA — has generated considerable interest among prescribers. However, providers are increasingly hearing from patients that they cannot get their Quviviq prescriptions filled.

This post provides a clinical and operational summary of the current Quviviq availability landscape, including supply status, insurance dynamics, cost considerations, and practical tools to support patient access.

Supply Status: Is There a Formal Shortage?

As of early 2026, Quviviq is not listed on the FDA Drug Shortage Database. Idorsia Pharmaceuticals, the manufacturer, has not reported any manufacturing disruptions, raw material shortages, or distribution interruptions. The drug continues to be produced and distributed through standard pharmaceutical channels.

The access challenges patients report are driven by downstream pharmacy stocking decisions rather than upstream supply constraints. This is a critical distinction: the drug is available in the supply chain, but individual pharmacy locations frequently do not carry it.

Timeline and Context

• January 2022: FDA approval of Daridorexant (Quviviq) for adults with insomnia characterized by sleep onset and/or sleep maintenance difficulties
• May 2022: Commercial availability in the United States following DEA Schedule IV classification
• 2022–2025: Gradual market uptake, with prescribing concentrated among sleep medicine specialists, psychiatrists, and neurologists
• 2026: No generic available. Patents extend through 2034. Patent challenges eligible from April 2026, but generic launch remains distant.

Prescribing Implications

When prescribing Quviviq, providers should be aware of several practical barriers that may affect patient adherence and access:

Pharmacy Stocking

Many retail pharmacies — particularly large chain locations — do not routinely stock Quviviq due to low individual-location demand. Patients may need to:

• Call multiple pharmacies before finding one that has it
• Wait for a special order (typically 1–2 business days at independent pharmacies)
• Use mail-order pharmacy services

Proactively directing patients to tools like Medfinder for Providers can reduce fill delays and improve the patient experience.

Insurance and Prior Authorization

Quviviq frequently requires prior authorization across commercial, Medicare, and Medicaid plans. Key considerations:

• Step therapy: Many formularies require trial and failure of Belsomra (Suvorexant) or Dayvigo (Lemborexant) before covering Quviviq
• Tier placement: Typically placed on Tier 3 (preferred brand) or higher, resulting in elevated patient copays
• Documentation: PA requests often require documentation of prior insomnia treatment history, diagnosis confirmation, and clinical rationale for Quviviq specifically

Consider documenting prior treatment trials and rationale for DORA selection proactively in the patient chart to streamline the PA process when it arises.

Dosing Considerations

Quviviq is available in 25 mg and 50 mg tablets, taken once nightly within 30 minutes of bedtime, with at least 7 hours before planned awakening. Key dosing interactions to consider:

• Moderate CYP3A4 inhibitors (e.g., Diltiazem, Erythromycin, Fluconazole, Verapamil): Maximum dose is 25 mg
• Strong CYP3A4 inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Ritonavir): Concomitant use is not recommended
• Strong/moderate CYP3A4 inducers (e.g., Rifampin, Carbamazepine, Phenytoin): Avoid concomitant use — may significantly reduce efficacy

For comprehensive interaction information, see: Quviviq Drug Interactions: What to Avoid.

The Availability Picture

The practical availability of Quviviq varies significantly by setting:

• Large chain pharmacies (CVS, Walgreens, Rite Aid): Stocking is inconsistent. Individual locations may or may not carry it based on local prescribing volume.
• Independent pharmacies: Generally more willing to special-order, but may not stock routinely either.
• Mail-order pharmacies: Typically the most reliable source, as they serve a broader geographic patient base and carry a wider formulary.
• Specialty pharmacies: Some specialty pharmacy networks carry Quviviq as part of their insomnia or CNS portfolios.

Cost and Access Landscape

Understanding the cost dynamics helps set realistic expectations with patients:

• Average cash price: $550–$680 per 30-day supply
• QUVIVIQ360 copay card: Eligible commercially insured patients may pay as little as $25/month. Managed by ConnectiveRx/vitaCare on behalf of Idorsia.
• Discount card pricing: GoodRx and similar platforms may offer prices starting around $135 at select pharmacies
• Patient assistance: Patients without insurance or with financial hardship can explore options through QUVIVIQ360, NeedyMeds, and RxAssist

Note: The manufacturer copay card is not valid for patients on government insurance (Medicare, Medicaid, Tricare, VA).

Tools and Resources for Your Practice

Several resources can help streamline Quviviq access for your patients:

Medfinder for Providers

Medfinder allows providers and staff to quickly check which pharmacies near a patient's location currently have Quviviq in stock. This can be integrated into your prescribing workflow to direct e-prescriptions to pharmacies that can actually fill them.

QUVIVIQ360

Idorsia's QUVIVIQ360 program provides:

• Copay savings cards for eligible patients
• Prescription fulfillment support through vitaCare
• Prior authorization assistance resources

Prescription Transfer

If a patient's usual pharmacy doesn't stock Quviviq, the prescription can be electronically sent to a pharmacy identified through Medfinder or QUVIVIQ360. This is typically a straightforward process.

Alternative Agents to Consider

When Quviviq is not accessible or appropriate, consider these alternatives within the DORA class:

• Belsomra (Suvorexant): 10–20 mg nightly. Longer half-life (~12 hours). May have slightly more next-day somnolence.
• Dayvigo (Lemborexant): 5–10 mg nightly. Longest half-life in the class (~17–19 hours). More OX2-selective.

For patients where cost is the primary barrier and a DORA is not essential, generic Zolpidem or Eszopiclone remain widely available and affordable options, albeit with a different mechanism and side effect profile. See: Alternatives to Quviviq.

Looking Ahead

The DORA class continues to expand. Vornorexant and other next-generation orexin receptor antagonists are in clinical development and may offer additional options in the coming years. As the class matures, competition may also drive improvements in pricing and insurance coverage.

In the meantime, patent challenges for Quviviq become eligible in April 2026, though actual generic availability remains years away given the patent estate extending through 2034.

Final Thoughts

Quviviq represents a meaningful advance in insomnia treatment, but practical access remains a challenge for many patients in 2026. Providers can improve patient outcomes by proactively addressing availability, directing patients to tools like Medfinder, documenting prior treatment history to streamline prior authorizations, and familiarizing patients with available savings programs.

For a patient-facing perspective on this issue, you may also want to share: Quviviq Shortage Update: What Patients Need to Know in 2026.